Lifecore Biomedical, Inc. (LFCR)
NASDAQ: LFCR · Real-Time Price · USD
4.150
+0.060 (1.47%)
Sep 10, 2026, 11:02 AM EDT - Market open
Lifecore Biomedical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | May '25 May 25, 2025 | May '24 May 26, 2024 | May '23 May 28, 2023 | May '22 May 29, 2022 |
| 129.46 | 128.87 | 128.26 | 103.27 | 111.27 | |
Revenue Growth | 0.46% | 0.47% | 24.20% | -7.19% | 10.31% |
Cost of Revenue | 88.85 | 88.57 | 86.41 | 75.28 | 72.2 |
Gross Profit | 40.61 | 40.3 | 41.85 | 27.99 | 39.07 |
Selling, General & Admin | 33.35 | 44.05 | 38.76 | 38.97 | 34.66 |
Research & Development | 8.51 | 8.26 | 8.58 | 8.74 | 7.84 |
Operating Expenses | 41.87 | 52.3 | 47.34 | 47.71 | 42.5 |
Operating Income | -1.26 | -12.01 | -5.49 | -19.72 | -3.43 |
Interest Expense | -27.17 | -22.17 | -18.15 | -17.58 | -15.47 |
Interest & Investment Income | 0.47 | 0.33 | 0.06 | - | - |
Other Non Operating Income (Expenses) | -2.26 | 0.41 | 36.45 | -0.81 | 6.57 |
EBT Excluding Unusual Items | -30.21 | -33.44 | 12.87 | -38.11 | -12.33 |
Merger & Restructuring Charges | - | 1.75 | -1.66 | -4.18 | -8.36 |
Gain (Loss) on Sale of Assets | - | -6.99 | - | 2.11 | - |
Other Unusual Items | - | - | -1.7 | -23.74 | - |
Pretax Income | -30.21 | -38.67 | 9.51 | -63.93 | -20.69 |
Income Tax Expense | 0.58 | 0.04 | 0.18 | 0.31 | -5.21 |
Earnings From Continuing Operations | -30.79 | -38.72 | 9.33 | -64.24 | -15.48 |
Earnings From Discontinued Operations | - | - | 2.68 | -35.33 | -101.24 |
Net Income to Company | -30.79 | -38.72 | 12.01 | -99.56 | -116.72 |
Net Income | -30.79 | -38.72 | 12.01 | -99.56 | -116.72 |
Preferred Dividends & Other Adjustments | 3.71 | 5.64 | - | - | - |
Net Income to Common | -34.5 | -44.36 | 12.01 | -99.56 | -116.72 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 37 | 35 | 30 | 30 | 29 |
Shares Outstanding (Diluted) | 37 | 35 | 37 | 30 | 29 |
Shares Change | 7.33% | -5.02% | 22.36% | 1.67% | 0.59% |
EPS (Basic) | -0.92 | -1.27 | 0.39 | -3.32 | -3.96 |
EPS (Diluted) | -0.93 | -1.27 | 0.33 | -3.32 | -3.97 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | May '25 May 25, 2025 | May '24 May 26, 2024 | May '23 May 28, 2023 | May '22 May 29, 2022 |
Free Cash Flow | 6.23 | -13.62 | -18.14 | -38.92 | -52.53 |
Free Cash Flow Per Share | 0.17 | -0.39 | -0.49 | -1.30 | -1.78 |
Gross Margin | 31.37% | 31.27% | 32.63% | 27.10% | 35.11% |
Operating Margin | -0.97% | -9.32% | -4.28% | -19.10% | -3.08% |
Profit Margin | -26.65% | -34.42% | 9.37% | -96.41% | -104.89% |
Free Cash Flow Margin | 4.81% | -10.57% | -14.14% | -37.69% | -47.21% |
EBITDA | 8.24 | -3.98 | 2.47 | -7.04 | 14.23 |
EBITDA Margin | 6.37% | -3.09% | 1.92% | -6.82% | 12.79% |
D&A For EBITDA | 9.5 | 8.03 | 7.95 | 12.68 | 17.66 |
EBIT | -1.26 | -12.01 | -5.49 | -19.72 | -3.43 |
EBIT Margin | -0.97% | -9.32% | -4.28% | -19.10% | -3.08% |
Effective Tax Rate | - | - | 1.92% | - | - |
Revenue as Reported | 129.46 | 128.87 | 128.26 | 103.27 | 111.27 |
Advertising Expenses | - | - | - | 0.01 | 0.01 |